Bölüm "Klinik und Poliklinik für Innere Medizin II, Technical University of Munich, Germany; Department of Histology and Embryology, Manisa Celal Bayar University, Turkey; Department of Biology, McMaster University, Hamilton, Ontario, Canada; Institute of Molecular Oncology and Functional Genomics and; Institute of Pathology, Technical University of Munich, Munich, Germany; Institute for Developmental Cancer Therapeutics, West German Cancer Center, University Hospital Essen, Essen, Germany; Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK) partner site Essen, Essen, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany" için listeleme

Toplam kayıt 1, listelenen: 1-1

    • Loss of Wasl improves pancreatic cancer outcome 

      Hidalgo-Sastre, A. and Desztics, J. and Dantes, Z. and Schulte, K. and Ensarioglu, H.K. and Bassey-Archibong, B. and Öllinger, R. and Engleiter, T. and Rayner, L. and Einwächter, H. and Daniel, J.M. and Altaee, A.S.A. and Steiger, K. and Lesina, M. and Rad, R. and Reichert, M. and von Figura, G. and Siveke, J.T. and Schmid, R.M. and Lubeseder-Martellato, C. (NLM (Medline), 2020)
      Several studies have suggested an oncogenic role for the neural Wiskott-Aldrich syndrome protein (N-WASP, encoded by the Wasl gene), but thus far, little is known about its function in pancreatic ductal adenocarcinoma ...